COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03969121
Recruitment Status : Recruiting
First Posted : May 31, 2019
Last Update Posted : August 12, 2020
Information provided by (Responsible Party):
Kyoto Breast Cancer Research Network

Brief Summary:
The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy over Endocrine therapy alone measured by PEPI and EndoPredict™ EPclin Score in women with operable HR+, HER2 negative breast cancer . The Clinical Response Rate, drop in Ki67 index ≤ 2.7% and Breast conserving rate will be compared between two arms.

Condition or disease Intervention/treatment Phase
Breast Cancer Female Hormone Receptor Positive Malignant Neoplasm of Breast Drug: Palbociclib Drug: Endocrine therapy Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Actual Study Start Date : July 16, 2019
Estimated Primary Completion Date : December 30, 2020
Estimated Study Completion Date : June 1, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Palbociclib

Arm Intervention/treatment
Active Comparator: Placebo + Endocrine therapy
Endocrine therapy for 16 weeks plus placebo
Drug: Endocrine therapy
Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.

Active Comparator: Palbociclib + Endocrine therapy
Endocrine therapy for 16 weeks plus Palbociclib
Drug: Palbociclib
Palbociclib will be administered orally once a day for 21 days every 28-day cycle followed by 7 days off treatment

Drug: Endocrine therapy
Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.

Primary Outcome Measures :
  1. Pre-operative Endocrine Prognostic Index (PEPI Score) [ Time Frame: 4 months ]

    The PEPI score is derived from four factors assigned a numerical score following neoadjuvant endocrine therapy, ( including Ki67 expression in the surgical specimen, pathologic tumor size, lymph node status, and estrogen receptor (ER) level).

    The PEPI score is the sum of each component score and shows the risk points for relapse-free survival. PEPI=0 means low risk. PEPI= 1 to 3 means intermediate risk .

    PEPI more than 4 means high risk.

  2. EndoPredict™ EPclin Score [ Time Frame: 4 months ]

    EndoPredict is a multigene test used to predict the risk of distant recurrence of early stage, ER positive ,HER-2 Negative invasive breast cancer. EndoPredict Clinical Score (EP clin ) categorizes patinets into low and high risk groups.Combination of the 12-Gene Molecular Score, tumor stage and lymph node status, generating an EPclin Risk Score.The EPclin Risk Score is calculated, according to the model, as:

    EPclin Risk Score = (0.35 * tumor size) + (0.64 * lymph node status) + (0.28 * 12-Gene Molecular Score) EPclin Risk Scores from 1.0 through 3.3 shows low risk of recurrencein 10 years.EPclin Risk Scores from 3.4 through 6.0 shows high risk of recurrence in 10 years.

Secondary Outcome Measures :
  1. Clinical Response Rate [ Time Frame: 4 months ]
    Observing any reduction in largest tumor diameter on clinical breast examination and ultrasound imaging of breast and axilla after 4 months

  2. Ki67 change [ Time Frame: 4 months ]
    Drop in Ki67 index to less than or equal to 2.7%

  3. pathological response rate [ Time Frame: 4 months ]
    Evaluating the rate of pathological Complete Response based on assessment of surgical specimen

  4. Breast conserving rate [ Time Frame: 4 months ]
    Calculating the rate of breast conserving surgery based on the number of each surgery type

  5. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment as Assessed by CTCAE v4.03 [ Time Frame: 4 months ]
    Type, incidence, severity (as graded by National Cancer Institute - Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03), seriousness and relationship to study medications of adverse events (AE) and any laboratory abnormalities

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Pre/peri- or post-menopausal women 18 years and older (or local legal age, whichever is higher)
  2. Primary tumor greater than 15 mm in diameter
  3. Histologically proven invasive breast cancer
  4. Positive hormone receptor (ER and/or PgR ≥1% in proportion of positive staining score)
  5. Negative HER-2 receptor (based on 2018 ASCO/CAP Guideline)
  6. Ki67 index equal to or greater than 14% (Ki67 ≥ 14%) by central assessment using actual or virtual slides
  7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 1
  8. No previous history of radiotherapy or systemic therapy including chemotherapy and hormone therapy for breast cancer
  9. Laboratory values must be as follows:

    Absolute neutrophil count: ≥ 1,500/mm3

    Platelets: ≥ 100,000/mm3

    Hemoglobin: ≥ 9 g/dL

    Bilirubin: ≤ 1.5 × upper limits of normal (ULN)

    Serum Creatinine: ≤ 1.5 × ULN

    Alkaline phosphatase: ≤ 2 × ULN

    AST and ALT: ≤ 2 × ULN

    Cardiac function: Normal finding of Electrocardiogram (ECG) QTc ≤ 480 msec (based on the mean value of the triplicate ECGs).

  10. Able to give written informed consent form
  11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures

Exclusion Criteria:

  1. Male
  2. Locally advanced breast cancer ( Any T4 or Any N2, N3), or distant metastasis
  3. Multicentric breast cancer (Note: Multifocal breast cancer,located in one quadrant/are is eligible)
  4. Prior treatment with chemotherapy, radiotherapy and/or endocrine therapy
  5. Previous use of SERMs such as raloxifene.
  6. Prior therapy with any CDK4/6 inhibitor or with everolimus, or any agent whose mechanism of action is to inhibit the PI3K-mTOR pathway.
  7. Prior history of other malignancy within 5 years of study entry, aside from basal cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix
  8. Major surgery within 3 weeks of first study treatment
  9. Patients treated within the last 7 days prior to randomization with:

    • Food or drugs that are known strong and moderate CYP3A4 inhibitors (e.g., amprenavir, aprepitant, atazanavir, boceprevir, casopitant, cimetidine, ciprof-loxacin, clarithromycin, conivaptan, cobicistat, crizotinib, cyclosporine, da-runavir, diltiazem, dronedarone, elvitegravir, erythromycin, fluconazole, fosamprenavir, imatinib, indinavir, isavuconazole, istradefylline, itraconazole,ketoconazole, letermovir, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, nilotinib, posaconazole, ritonavir, saquinavir, schisandra sphenan-thera extract, telaprevir, telithromycin, tofisopam, verapamil, voriconazole, and grapefruit, grapefruit juice or any product containing grapefruit);
    • Drugs that are known strong and moderate CYP3A4 inducers (e.g., bosentan, carbamazepine, efavirenz, etravirine, modafinil, phenobarbital, phenytoin, ri-fampin, rifapentin, and St. John's wort);
  10. Any of the following in the previous 6 months of randomization: myocardial in-farction, severe/unstable angina, ongoing cardiac dysrhythmias of NCI CTCAE version 4.03 grade ≥ 2, atrial fibrillation of any grade, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident in-cluding transient ischemic attack, or symptomatic pulmonary embolism
  11. Family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation, or Torsade de Pointes (TdP).
  12. Uncontrolled electrolyte disorders (eg, hypocalcemia, hypokalemia, hypomag-nesemia) that can compound the effects of a QTc-prolonging drug.
  13. Active inflammatory bowel disease or chronic diarrhea. Short bowel syndrome. Upper gastrointestinal surgery including gastric resection.
  14. Prior hematopoietic stem cell or bone marrow transplantation.
  15. Known abnormalities in coagulation such as bleeding diathesis, or treatment with anticoagulants precluding subcutaneous injections of leuprorelin or goserelin.
  16. Hepatitis B and/or hepatitis C carriers (Patients with HBsAg+ or HBV-DNA+ who need antiviral treatment during any anti-cancer therapy based on guidelines are excluded even if the patient's hepatic function is normal. Patients with HCVAb+, whose HCV-RNA is positive (+) are excluded.)
  17. Known human immunodeficiency virus (HIV) infection
  18. Known hypersensitivity to anti-aromatase drugs, tamoxifen or any cell cycle in-hibitor.
  19. Patients who are pregnant or lactating. Patients of childbearing potential and/or her partner who are unwilling or unable to use a method of highly effective non-hormonal contraception throughout the study and continue for at least 21 days in patients after the last dose of investigational drug.
  20. Other severe acute or chronic medical or psychiatric condition, or laboratory ab-normality that would impart, in the judgment of the investigator, excess risk as-sociated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study
  21. Patients who are investigational site staff members or relatives of those site staff OOTR-N016/KBCRN-B-003/HT-PAB Protocol (version 1.2 dated Oct 11, 2018) 24 members or patients who are the sponsor employees directly involved in the con-duct of the trial.
  22. Participation in other studies involving investigational drug (s) (Phases 1-4) within 2 weeks before randomization and/or until a visit at 4 weeks (+7 days) after operation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03969121

Layout table for location contacts
Contact: Elham Fakhrejahani, MD,PhD 0755857861

Show Show 27 study locations
Sponsors and Collaborators
Kyoto Breast Cancer Research Network
Layout table for investigator information
Principal Investigator: Masakazu Toi, MD,PhD Kyoto University, Professor of Breast Surgery Department
Principal Investigator: Louis WC Chow, MD,PhD Organisation for Oncology and Translational Research (OOTR)
Principal Investigator: Takayuki Ueno, MD,PhD Cancer Institute Hospital of JFCR, Department Director, Breast Surgical Oncology Department
Layout table for additonal information
Responsible Party: Kyoto Breast Cancer Research Network Identifier: NCT03969121    
Other Study ID Numbers: OOTR-N016/KBCRN-B-003/HT-PAB
First Posted: May 31, 2019    Key Record Dates
Last Update Posted: August 12, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Kyoto Breast Cancer Research Network:
Breast Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action